Compare Ingersoll Rand (IR) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ingersoll Rand vs Travere Therapeutics Inc. Common Stock — how do they compare? Ingersoll Rand trades at $77.95 (market cap $30.63B), while Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B). The key difference: Ingersoll Rand is far larger — about 6.3× Travere Therapeutics Inc. Common Stock's market cap, and Ingersoll Rand pays a 0.1% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Ingersoll Rand for 9 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| IR | TVTX | |
|---|---|---|
Market Cap | $30.63B | $4.88B |
Volume | 3,342,496 | 1,668,577 |
Sector | Industrials | Health |
52-Week High | $98.76 | $67.52 |
52-Week Low | $68.54 | $26.79 |
Typical Hold Time | 9 Days | 0 Days |
Enterprise Value | $34.29B | $5.01B |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ingersoll Rand (IR) trades at $78.95, down 0.18% with a bullish technical signal. The company shows strong fundamentals with Q2 2026 EPS beating estimates at $0.86 versus $0.827 expected, marking three consecutive quarterly beats. Revenue guidance was raised to 4.5%-6.5% for 2026, with improving demand across business cycles. Analyst consensus is bullish with a $90.60 price target, representing 15% upside potential from current levels.
The outlook remains positive with accelerating long-cycle orders and strategic acquisitions expanding capabilities. Key risks include margin compression and elevated P/E ratio of 32.62. Institutional ownership increased with HSBC boosting its position by 12.9% in Q2 2026. The stock offers growth potential but requires monitoring of profitability trends and valuation sustainability.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Ingersoll Rand
Ingersoll Rand develops industrial technologies for creating and managing flow, pressure, and motion. Its portfolio includes compressors, pumps, vacuum systems, and other equipment used across industrial markets.
Read more on IR →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
